Our Science
Our Approach
Defined Bacterial Consortia
Product Engine
Manufacturing
Intellectual Property
Scientific Insights
Publications
Pipeline & Programs
Pipeline
VE303
VE707
VE202
Commitment to Patients
Our Focus
How It Works
Disease Areas
C. difficile
Infection
Inflammatory Bowel Disease
Clinical Trials
Trials
RESTORATiVE303
COLLECTiVE202
Expanded Access Policy
Who We Are
Company
Mission
Leadership
Team
Board of Directors
Scientific Advisory Board
Partnerships
Careers
Working at Vedanta
Open Positions
News
Press Releases
Our Science
Defined Bacterial Consortia
Product Engine
Manufacturing
Intellectual Property
Publications
Pipeline & Programs
Pipeline
VE303
VE707
VE202
Commitment to Patients
How It Works
C. difficile
Infection
Inflammatory Bowel Disease
Trials
RESTORATiVE303
COLLECTiVE202
Expanded Access Policy
Who We Are
Mission
Leadership
Team
Board of Directors
Scientific Advisory Board
Partnerships
Working at Vedanta
Open Positions
News
Press Releases
Press Releases
Year
All
2025
2024
2023
2022
June 28, 2022
Vedanta Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia
June 8, 2022
Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference
May 24, 2022
Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting
April 13, 2022
Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results
Pages:
1
2
3
Load More
Sorry, nothing found in this query
